# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
IRADIMED CORPORATION ("Iradimed") (NASDAQ:IRMD), a leading provider of innovative magnetic resonance imaging (MRI) comp...
iRadimed (NASDAQ:IRMD) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.34 by 5.8...
Roth MKM analyst Jason Wittes reinstates iRadimed (NASDAQ:IRMD) with a Buy and announces $65 price target.
- SEC Filing